Reed’s MsFLASH review compares nonhormonal medicines with oral estradiol for hot flashes and highlights telephone CBT for sleep.
On October 23, 2026, Contemporary OB/GYN published an interview in which Susan Reed discussed pooled findings from MsFLASH, an NIH-funded menopause clinical-trials network. Speaking at the Menopause Society’s annual meeting in San Diego, Reed reported similar hot-flash efficacy for tested nonhormonal medicines and low-dose oral estradiol.
The report adds comparative context to a standard that still places hormone therapy first for menopausal vasomotor symptoms, including hot flashes. The American College of Physicians’ October 2026 recommendations list estrogen-based therapy as first-line treatment. They include progestogen for people with a uterus and suggest venlafaxine or desvenlafaxine when estrogen is contraindicated or not tolerated.
That is the starting point the MsFLASH discussion refines rather than overturns. The useful question is not simply whether a treatment contains hormones. It is which supported option fits the symptom being addressed and the person seeking care.
Reed’s account brings together two treatment questions: how well the studied medicines performed for hot flashes and which intervention stood out for sleep. The findings are most useful when those outcomes remain separate.
The clearest practical application is to organise the conversation around the outcome being sought. This is not a treatment-selection protocol. It is a way to bring Reed’s reported comparisons into the shared decision-making approach described by ACOG.
When hot flashes are the priority, discuss the hormonal and nonhormonal evidence together. Reed’s account provides a specific reason to ask about escitalopram and venlafaxine alongside hormone therapy. The ACP recommendations provide the guideline context for that conversation. A question such as “How does this evidence relate to the options appropriate for my medical history?” keeps the discussion tied to both research and individual care. The purpose is to understand the available choices with a qualified clinician rather than select a medicine from a headline.
When sleep is the priority, name that goal explicitly. Reed’s report gives telephone-delivered CBT a particular place in the discussion. A useful question is whether that form of CBT is relevant to the sleep problem being discussed and whether it is available through the care setting. This keeps the focus on the intervention described in the research. It also gives the clinician a clear account of the outcome the woman wants help addressing.
When several concerns compete for attention, establish the treatment priorities. ACOG’s guidance makes those priorities part of shared decision-making. Someone seeking care may want the conversation to begin with hot flashes or with sleep. Making that preference explicit gives the appointment a clearer focus without suggesting that other concerns matter less. Refemina’s coverage of matching menopause care to specific symptoms offers related context for reading treatment evidence by outcome.
Keep symptom relief connected to the wider purpose of care. The value of discussing treatment is not to turn midlife into a sequence of medical decisions. It is to make the evidence useful to the woman seeking help. Refemina’s perspective on midlife change without pressure to feel positive places symptom conversations within that broader experience. A clear clinical priority and a wider view of life can sit together.
These questions leave the treatment decision where it belongs: in a conversation with a qualified clinician who can relate the evidence to personal circumstances. They also give the appointment a more precise starting point than asking for the single best menopause treatment. Hot-flash relief and better sleep are distinct goals, and the MsFLASH account gives each a specific evidence-based discussion point.
In the Contemporary OB/GYN interview, Reed said pooling results across trials allowed researchers to “answer a bigger question.” She described the resulting evidence as “a very solid anchor for clinicians to be able to use with their patients.”
That is a useful way to understand the report’s contribution. An anchor gives a discussion something firmer to rest on. Here, it is a comparison clinicians can bring into conversations about hot-flash medicines and a separate finding that draws attention to telephone-delivered CBT for sleep.
The practical direction is more outcome-specific menopause care, with clinicians using the MsFLASH comparisons to inform individualized discussions about hot-flash relief and sleep.
Fewer hot flashes and better sleep are concrete outcomes against which menopause treatment claims can be judged. Refemina translates research on hormonal transition and midlife wellbeing into clear guidance that separates clinical findings from promotional claims while treating confidence and quality of life as legitimate parts of women’s health.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources